DES Exposure: New Research Brings Clarity to Long-Term Health Risks
A recent study by the Antoni van Leeuwenhoek (AVL) offers reassuring news for women exposed to diethylstilbestrol (DES) before birth. The long-term research indicates that DES daughters do not face an elevated risk of breast cancer. However, the risk of vaginal cancer remains a concern, even beyond the age of 50.
Understanding the DES Legacy
Between 1947 and 1976, DES was prescribed in the Netherlands to pregnant women to prevent miscarriages. Unfortunately, it was later discovered that DES had adverse effects on both the mothers and their children. DES daughters, in particular, experienced a higher incidence of genital abnormalities and an increased risk of rare vaginal or cervical cancers at a young age.
This research aimed to provide answers regarding the long-term health implications for women who were exposed to DES in the womb. Prior research raised concerns about a potential increased risk of breast cancer due to higher estrogen exposure during pregnancy. The new study, however, offers some relief.
Key Findings: Breast Cancer Risk and Beyond
The AVL study involved over 12,000 DES daughters, comparing their data with that of their unexposed sisters and the general population. Researchers utilized questionnaires, data from the Dutch Cancer Registry, and the PALGA pathology database to assess cancer risks, focusing on age, diagnosis year, and gender.
The good news? The study found no elevated risk of breast cancer, ovarian cancer, melanoma, or other common cancers for DES daughters. However, the increased risk of vaginal cancer, particularly two types – clear cell adenocarcinoma and squamous cell carcinoma – persisted.
Did you know? Although the risk of vaginal cancer is higher in DES daughters, it remains a rare cancer. The study estimated that, among 1,000 DES daughters aged 50, no more than one woman would receive this diagnosis before age 65.
Implications and Future Directions
Epidemiologist Floor van Leeuwen from the AVL emphasized the reassuring nature of the findings for many women. The research clearly indicates that, beyond the known risk of vaginal cancer, there is no evidence of additional risks.
This research provides clarity and peace of mind for many DES daughters, contributing to an improved quality of life. Understanding personal health risks empowers women to manage their health concerns effectively. Currently, DES daughters undergo regular screenings with Pap smears up to age 60, according to the DES screening protocol. Researchers are recommending a review of whether this age limit should be extended, and the Cervix Uteri working group of the Dutch Society for Obstetrics and Gynecology (NVOG) is currently reviewing the matter.
Pro Tips for DES Daughters
- Regular Screenings: Continue with recommended screenings, including Pap smears, as advised by your healthcare provider.
- Open Communication: Discuss any health concerns with your doctor, including your DES exposure history.
- Stay Informed: Stay updated on research and guidelines related to DES exposure and its potential long-term effects.
Frequently Asked Questions
- What is DES? Diethylstilbestrol (DES) is a synthetic estrogen prescribed to pregnant women in the past to prevent miscarriages.
- What are the risks for DES daughters? DES daughters face an increased risk of vaginal cancer and genital abnormalities.
- Does this new research change the recommendations? The research clarifies that there is no increased risk of breast cancer but reinforces the importance of vaginal cancer screening.
- Where can I find more information about DES? Contact the DES Centre (DES Centrum) for further information and support.
For further reading on the study, see the research published in the Springer link.
This research was funded by KWF Kankerbestrijding and the DES Centre.
We want to hear from you! Do you have any experiences or questions related to DES exposure? Share your thoughts and comments below. Your insights can help others.
